American Journal of Epidemiology Vol. 152, No. 10 : 923-933
Copyright © 2000 by The Johns Hopkins University School of Hygiene and Public Health
ORIGINAL CONTRIBUTIONS |
Selection by Indication of Potent Antiretroviral Therapy Use in a Large Cohort of Women Infected with Human Immunodeficiency Virus
1 Department of Epidemiology, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD.
2 Department of Medicine, University of California, San Francisco, San Francisco, CA.
3 Department of Obstetrics and Gynecology, Maimonides Medical Center and SUNY Health Science Center at Brooklyn, Brooklyn, NY.
4 Department of Internal Medicine, Montefiore Medical Center, Bronx, NY.
5 Department of Internal Medicine, Infectious Disease, Georgetown University Medical Center, Washington, DC.
6 Department of Pediatrics, University of Southern California School of Medicine, Los Angeles, CA.
7 Comprehensive Maternal-Child and Adolescent HIV Management and Research Center, University of Southern California School of Medicine, Los Angeles, CA.
8 Department of Medicine, Cook County Hospital, Chicago, IL.
To characterize selection factors related to therapy initiation, the authors investigated the extent to which key markers of human immunodeficiency virus (HIV) disease severity were associated with initiation of potent antiretroviral therapy (ART). Logistic regression was used to determine the effects of CD4+ cell count and HIV RNA level on potent ART initiation during 6-month periods among 2,059 HIV-infected US women enrolled in the Women's Interagency HIV Study. Low CD4+ counts and high HIV RNA levels were significantly (p < 0.05) associated with initiation of potent ART. During all periods between April 1996 and March 1998, CD4+ counts were more strongly associated with potent ART initiation than HIV RNA levels were; however, during the last period, both were associated (odds ratio per 100 CD4+-count decrease = 1.17, p < 0.01; odds ratio per 1 log10 increase in HIV RNA level = 1.48, p < 0.05). For a CD4+ count of 500 cells/ml and an HIV RNA level of 5,000 copies/ml, the probability of potent ART initiation increased from 0.5% to16.8% between October 1995–March 1996 and October 1997–March 1998, suggesting earlier initiation of potent ART. Given the documented occurrence of confounding by indication, prospectively collected, time-dependent data on markers of disease progression and therapy use should be considered when making population-level comparisons before and after introduction of potent ART. Am J Epidemiol 2000;152:923–33.
CD4 lymphocyte count; confounding factors (epidemiology); HIV; RNA; therapeutics
Abbreviations: AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; HIV, human immunodeficiency virus
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. R. Cole, M. A. Hernan, K. Anastos, B. D. Jamieson, and J. M. Robins Determining the Effect of Highly Active Antiretroviral Therapy on Changes in Human Immunodeficiency Virus Type 1 RNA Viral Load using a Marginal Structural Left-censored Mean Model Am. J. Epidemiol., July 15, 2007; 166(2): 219 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Cole, M. A. Hernan, J. B. Margolick, M. H. Cohen, and J. M. Robins Marginal Structural Models for Estimating the Effect of Highly Active Antiretroviral Therapy Initiation on CD4 Cell Count Am. J. Epidemiol., September 1, 2005; 162(5): 471 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Storm, M. G. Boland, S. L. Gortmaker, Y. He, J. Skurnick, L. Howland, J. M. Oleske, and for the Pediatric AIDS Clinical Trials Group Proto Protease Inhibitor Combination Therapy, Severity of Illness, and Quality of Life Among Children With Perinatally Acquired HIV-1 Infection Pediatrics, February 1, 2005; 115(2): e173 - e182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ahdieh-Grant, R. Li, A. M. Levine, L. S. Massad, H. D. Strickler, H. Minkoff, M. Moxley, J. Palefsky, H. Sacks, R. D. Burk, et al. Highly Active Antiretroviral Therapy and Cervical Squamous Intraepithelial Lesions in Human Immunodeficiency Virus-Positive Women J Natl Cancer Inst, July 21, 2004; 96(14): 1070 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Wilson, M. E. Gore, R. Greenblatt, M. Cohen, H. Minkoff, S. Silver, E. Robison, A. Levine, and S. J. Gange Changes in Sexual Behavior Among HIV-Infected Women After Initiation of HAART Am J Public Health, July 1, 2004; 94(7): 1141 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Anastos, Y. Barron, M. H. Cohen, R. M. Greenblatt, H. Minkoff, A. Levine, M. Young, and S. J. Gange The Prognostic Importance of Changes in CD4+ Cell Count and HIV-1 RNA Level in Women after Initiating Highly Active Antiretroviral Therapy Ann Intern Med, February 17, 2004; 140(4): 256 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Greenspan, S.J. Gange, J.A. Phelan, M. Navazesh, M.E.A.F. Alves, L.A. MacPhail, R. Mulligan, and J.S. Greenspan Incidence of Oral Lesions in HIV-1-infected Women: Reduction with HAART J. Dent. Res., February 1, 2004; 83(2): 145 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Cole, M. A. Hernan, J. M. Robins, K. Anastos, J. Chmiel, R. Detels, C. Ervin, J. Feldman, R. Greenblatt, L. Kingsley, et al. Effect of Highly Active Antiretroviral Therapy on Time to Acquired Immunodeficiency Syndrome or Death using Marginal Structural Models Am. J. Epidemiol., October 1, 2003; 158(7): 687 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ahdieh-Grant, T. E. Yamashita, J. P. Phair, R. Detels, S. M. Wolinsky, J. B. Margolick, C. R. Rinaldo, and L. P. Jacobson When to Initiate Highly Active Antiretroviral Therapy: A Cohort Approach Am. J. Epidemiol., April 15, 2003; 157(8): 738 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Anastos, Y. Barron, P. Miotti, B. Weiser, M. Young, N. Hessol, R. M. Greenblatt, M. Cohen, M. Augenbraun, A. Levine, et al. Risk of Progression to AIDS and Death in Women Infected With HIV-1 Initiating Highly Active Antiretroviral Treatment at Different Stages of Disease Arch Intern Med, September 23, 2002; 162(17): 1973 - 1980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. Jacobson, R. Li, J. Phair, J. B. Margolick, C. R. Rinaldo, R. Detels, and A. Munoz Evaluation of the Effectiveness of Highly Active Antiretroviral Therapy in Persons with Human Immunodeficiency Virus using Biomarker-based Equivalence of Disease Progression Am. J. Epidemiol., April 15, 2002; 155(8): 760 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S J Gange, Y Barron, R M Greenblatt, K Anastos, H Minkoff, M Young, A Kovacs, M Cohen, W A Meyer III, and A Munoz Effectiveness of highly active antiretroviral therapy among HIV-1 infected women J. Epidemiol. Community Health, February 1, 2002; 56(2): 153 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Buchacz, J. S. Cervia, J. C. Lindsey, M. D. Hughes, G. R. Seage III, W. M. Dankner, J. M. Oleske, J. Moye, and for the Pediatric AIDS Clinical Trials Group 219 S Impact of Protease Inhibitor-Containing Combination Antiretroviral Therapies on Height and Weight Growth in HIV-Infected Children Pediatrics, October 1, 2001; 108(4): e72 - 72. [Abstract] [Full Text] [PDF]
|
|